Company: TVRD
Filing Date: 2025-10-20
Form Type: S-1/A
Source: 0001104659-25-100896
Chunk: 328

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-10-20
Form: S-1/A
Chunk 328
---
 | ​ | ​ |
| 2029                    | ​ | ​ | ​      | ​ |  63 | ​ | ​ |
| Thereafter              | ​ | ​ | ​      | ​ |  70 | ​ | ​ |
| Total                   | ​ | ​ | ​      | $ | 385 | ​ | ​ |

The Company recognized less than $0.1 million for amortization expense for each of the years ended December 31, 2024 and 2023. Amortization expense is included in research and development expense in the statements of operations.

F-18

TABLE OF CONTENTS

6. Accrued Expenses Accrued expenses consisted of the following as of December 31, 2024 and 2023 (in thousands):

| ​                                          
 ​                                          | ​ 
 ​ | ​ 
 ​ | As of December 31, 
 2024               |   |       |   | ​ | ​ | 2023 |   |       |   | ​ 
 ​ |
|:-------------------------------------------|:--|:--|:-------------------|:--|------:|:--|:--|:--|:-----|:--|------:|:--|:--|
| Accrued research and development expenses  | ​ | ​ | ​                  | $ | 5,172 | ​ | ​ | ​ | ​    | $ |   518 | ​ | ​ |
| Accrued employee compensation and benefits | ​ | ​ | ​                  | ​ | 1,142 | ​ | ​ | ​ | ​    | ​ |   942 | ​ | ​ |
| Accrued professional fees                  | ​ | ​ | ​                  | ​ | 1,756 | ​ | ​ | ​ | ​    | ​ |   108 | ​ | ​ |
| Other accrued expenses                     | ​ | ​ | ​                  | ​ |     8 | ​ | ​ | ​ | ​    | ​ |     9 | ​ | ​ |
| Total accrued expenses                     | ​ | ​ | ​                  | $ | 8,078 | ​ | ​ | ​ | ​    | $ | 1,577 | ​ | ​ |

7. Leases The Company has one operating lease pertaining to 5,969 square feet of corporate office space in Sugar Land, Texas pursuant to a lease agreement that commenced April 1, 2022. As of December 31, 2024 the remaining